目的 探討采用血府逐瘀膠囊聯(lián)合丁苯酞治療缺血性腦血管的臨床效果。方法 選取秦皇島市中醫(yī)醫(yī)院在2016年3月—2017年3月收治的缺血性腦血管疾病患者161例，隨機(jī)分成對(duì)照組（80例）和治療組（81例）。對(duì)照組患者靜脈滴注丁苯酞氯化鈉注射液，100 mL/次，2次/d；治療組患者在對(duì)照組的基礎(chǔ)上口服血府逐瘀膠囊，6粒/次，2次/d。所有患者均經(jīng)過規(guī)律治療15 d。觀察兩組患者臨床療效，比較治療前后兩組患者臨床評(píng)分、基質(zhì)金屬蛋白酶-9（MMP-9）、腦血容量（CBV）和腦血流量（CBF）水平以及不良反應(yīng)情況。結(jié)果 治療后，對(duì)照組和治療組的臨床總有效率分別為86.25%和96.30%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者神經(jīng)功能缺損評(píng)分（NIHSS）評(píng)分明顯降低，簡(jiǎn)易智能精神狀態(tài)檢查量表（MMSE）和日常生活活動(dòng)能力量表（ADL）評(píng)分顯著升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組各臨床評(píng)分顯著優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者M(jìn)MP-9水平顯著降低，CBV和CBF水平顯著升高，同組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組MMP-9、CBV和CBF水平改善情況明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療期間，治療組不良反應(yīng)發(fā)生率為2.47%，顯著低于對(duì)照組患者的12.50%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 血府逐瘀膠囊聯(lián)合丁苯酞治療缺血性腦血管疾病療效顯著，安全性高，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Xuefu Zhuyu Capsules combined with butyphthalide in treatment of ischemic cerebrovascular diseases. Methods Patients (161 cases) with ischemic cerebrovascular diseases in Qinhuangdao Hospital of TCM from March 2016 to March 2017 were randomly divided into control (80 cases) and treatment (81 cases) groups. Patients in the control group were iv administered with Butylphthalide and Sodium Chloride Injection, 100 mL/time, twice daily. Patients in the treatment group were po administered with Xuefu Zhuyu Capsules on the basis of the control group, 6 grains/times, twice daily. Patients in two groups were treated for 15 d. After treatment, the clinical efficacy were evaluated, the clinical scores, MMP-9, CBV and CBF levels, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 86.25% and 96.30%, respectively, and there were differences between two groups (P < 0.05). After treatment, the NIHSS scores in two groups were significantly decreased, but MMSE and ADL scores were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the clinical scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, MMP-9 levels in two groups were significantly decreased, but CBV and CBF levels were significantly increased, and there were differences in the same group (P < 0.05). And the improvement of MMP-9, CBV and CBF levels in the treatment group was significantly better than that in the control group, with significant difference between two groups (P < 0.05). During the treatment, the incidence of adverse reactions in the treatment group was 2.47%, which was significantly lower than 12.50% in the control treatment group, with significant difference between two groups (P < 0.05). Conclusion Xuefu Zhuyu Capsules combined with butyphthalide has significant effect in treatment of ischemic cerebrovascular diseases with high safety, which has a certain clinical application value.